Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
39-40
pubmed:dateCreated
2007-9-18
pubmed:abstractText
Pre-clinical HIV-1 vaccine protocols, using multiple vaccine modalities and a potent adjuvant were assessed for vaccine efficacy in an experimental HIV-1 challenge model. C57Bl/6 mice were immunized with DNA plasmids encoding HIV-1 gp140, Gag and Tat alone or in combination with the corresponding recombinant proteins formulated in the adjuvant MF59. HIV-1 DNA alone or a DNA prime protein boost schedule resulted in complete protection against challenge with HIV-1/MuLV-infected murine cells. Although HIV-1 protein immunization in combination with MF59 resulted in partial protection, the DNA priming seemed to be crucial for obtaining full protection against the challenge. It is likely that the partial protection seen after immunization with protein alone is, to a certain extent, due to effects of the adjuvant since some animals that received the adjuvant MF59 alone were protected from the challenge. For the most part, antigen-specific cell-mediated immune responses as detected in the spleen (in contrast to responses detected in peripheral blood) of immunized animals appeared to be associated with protection in this study.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0264-410X
pubmed:author
pubmed:issnType
Print
pubmed:day
28
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6882-90
pubmed:meshHeading
pubmed-meshheading:17707956-AIDS Vaccines, pubmed-meshheading:17707956-Adjuvants, Immunologic, pubmed-meshheading:17707956-Animals, pubmed-meshheading:17707956-Disease Models, Animal, pubmed-meshheading:17707956-Gene Products, gag, pubmed-meshheading:17707956-Gene Products, tat, pubmed-meshheading:17707956-HIV Antibodies, pubmed-meshheading:17707956-HIV Infections, pubmed-meshheading:17707956-HIV-1, pubmed-meshheading:17707956-Humans, pubmed-meshheading:17707956-Immunization, pubmed-meshheading:17707956-Immunization Schedule, pubmed-meshheading:17707956-Immunoglobulin G, pubmed-meshheading:17707956-Leukemia Virus, Murine, pubmed-meshheading:17707956-Mice, pubmed-meshheading:17707956-Mice, Inbred C57BL, pubmed-meshheading:17707956-Mice, Transgenic, pubmed-meshheading:17707956-Polysorbates, pubmed-meshheading:17707956-Squalene, pubmed-meshheading:17707956-T-Lymphocytes, pubmed-meshheading:17707956-env Gene Products, Human Immunodeficiency Virus
pubmed:year
2007
pubmed:articleTitle
Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
pubmed:affiliation
Swedish Institute for Infectious Disease Control, Stockholm, Sweden. andreas.brave@smi.ki.se
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural